These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 6279117)

  • 1. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients.
    Whitman HH; Case DB; Laragh JH; Christian CL; Botstein G; Maricq H; Leroy EC
    Arthritis Rheum; 1982 Mar; 25(3):241-8. PubMed ID: 6279117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course of patients with scleroderma renal crisis treated with captopril.
    Zawada ET; Clements PJ; Furst DA; Bloomer HA; Paulus HE; Maxwell MH
    Nephron; 1981; 27(2):74-8. PubMed ID: 7022235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of captopril to reverse the renal crisis of scleroderma.
    Brown EA; Macgregor GA; Maini RN
    Ann Rheum Dis; 1983 Feb; 42(1):52-3. PubMed ID: 6338841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK, 421 (Enalapril) in captopril-intolerant patients.
    Smith CD; Smith RD; Korn JH
    Arthritis Rheum; 1984 Jul; 27(7):826-8. PubMed ID: 6331462
    [No Abstract]   [Full Text] [Related]  

  • 5. Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalization with captopril.
    Waeber B; Schaller MD; Wauters JP; Brunner HR
    Klin Wochenschr; 1984 Aug; 62(15):728-30. PubMed ID: 6387262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Special uses for captopril.
    Materson BJ
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):88-93. PubMed ID: 2886046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Improvement in scleroderma kidney with captopril].
    Ben David A; Blau A; Rapoport G
    Harefuah; 1994 Oct; 127(7-8):234-5, 287. PubMed ID: 7813949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Captopril in the treatment of scleroderma renal crisis.
    Thurm RH; Alexander JC
    Arch Intern Med; 1984 Apr; 144(4):733-5. PubMed ID: 6370160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scleroderma crisis: progressive renal failure despite blood-pressure control.
    DiPette DJ; Daisley SJ; Fragola JA
    Clin Pharm; 1983; 2(2):179-81. PubMed ID: 6349906
    [No Abstract]   [Full Text] [Related]  

  • 10. Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature.
    Logee KM; Lakshminarayanan S
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S171-4. PubMed ID: 25797912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors.
    Steen VD; Costantino JP; Shapiro AP; Medsger TA
    Ann Intern Med; 1990 Sep; 113(5):352-7. PubMed ID: 2382917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of captopril in the treatment of systemic arterial and pulmonary hypertension with increased plasma renin in scleroderma].
    Richard C; Ricome JL; Lemoine F; Rimailho A; Lantz O; Auzépy P
    Rev Med Interne; 1983 Jun; 4(2):125-9. PubMed ID: 6351212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scleroderma renal crisis.
    Prisant LM; Loebl DH; Mulloy LL
    J Clin Hypertens (Greenwich); 2003; 5(2):168-70, 176. PubMed ID: 12671333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.
    Lopez-Ovejero JA; Saal SD; D'Angelo WA; Cheigh JS; Stenzel KH; Laragh JH
    N Engl J Med; 1979 Jun; 300(25):1417-9. PubMed ID: 220537
    [No Abstract]   [Full Text] [Related]  

  • 15. [Administration of angiotensin I converting enzyme inhibitor captopril, in a case of renal crisis of scleroderma--the effects of captopril to the temperature of the skin lesion in scleroderma (author's transl)].
    Gotoh S; Ogihara T; Hata T; Maruyama A; Naka T; Nakamaru M; Mikami H; Masuo K; Kumahara Y
    Nihon Jinzo Gakkai Shi; 1981 Aug; 23(8):1133-41. PubMed ID: 7033607
    [No Abstract]   [Full Text] [Related]  

  • 16. Monotherapy of hypertension with angiotensin-converting enzyme inhibitors.
    Materson BJ
    Am J Med; 1984 Oct; 77(4A):128-34. PubMed ID: 6207725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of moderate to severe hypertensive patients with an orally active converting-enzyme inhibitor.
    Prins EJ; Donker AJ; Hoorntje SJ; Leenen FH; van der Hem GK
    Proc Eur Dial Transplant Assoc; 1979; 16():603-9. PubMed ID: 232914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
    MacGregor GA; Markandu ND; Roulston JE; Jones JC
    Br Med J; 1979 Nov; 2(6198):1106-9. PubMed ID: 229941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scleroderma renal crisis.
    Mouthon L; Bussone G; Berezné A; Noël LH; Guillevin L
    J Rheumatol; 2014 Jun; 41(6):1040-8. PubMed ID: 24833760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of captopril as early therapy for renal scleroderma: a prospective study.
    Beckett VL; Donadio JV; Brennan LA; Conn DL; Osmundson PJ; Chao EY; Holley KE
    Mayo Clin Proc; 1985 Nov; 60(11):763-71. PubMed ID: 3903366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.